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Background: Anal canal carcinoma is a rare neoplasm, representing 2% of the digestive
tumors, and the most common is squamous cell carcinoma, with an increasing incidence.
Objective: The study aims to elucidate the pathogenesis of an increasingly prevalent disease,
as  well as to update treatment and prognosis.
Methods: A literature search in Pubmed database, including articles from 2005 to 2015 and
cross-research articles with the initial research.
Results: Several studies prove the role of HPV as a major risk factor in the development
of  squamous cell carcinoma of anal canal, as well as a greater prevalence of this neopla-
sia in HIV-positive people and in those who practice receptive anal intercourse. In the last
two  decades chemoradiotherapy remains the treatment of choice, and abdominoperineal
resection is reserved for those cases of treatment failure or recurrence. Evidence advances
in  order to adapt the treatment to each patient, taking into account individual prognostic
factors and biological tumor characteristics.
Conclusions: Squamous cell carcinoma of the anal canal is a neoplasm associated with HPV;
therefore, screening and vaccination programs of male individuals, by way of prevention,
should be started. Many studies are needed in order to achieve development in the treatment
as  well as in the evaluation of the biological characteristics of the tumor.
©  2016 Sociedade Brasileira de Coloproctologia. Published by Elsevier Editora Ltda. This
is  an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
Carcinoma  epidermóide  do  canal  anal
alavras-chave:
r  e  s  u  m  o
Introduc¸ão: O carcinoma do canal anal é uma neoplasia rara, representando 2% dos tumores
arcinoma escamoso digestivos, sendo o epidermóide o mais comum com uma incidência crescente.
 pretende elucidar sobre a etiopatogenia desta patologia cada vez maisanal anal Objetivo: Este estudoPlease cite this article in press as: Magalhães MN, Barbosa LE. Anal canal squamous carcinoma. J Coloproctol (Rio J). 2016.
http://dx.doi.org/10.1016/j.jcol.2016.08.003
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prevalente, assim como atualizar sobre o tratamento e prognóstico.
Métodos: Pesquisa bibliográﬁca na base de dados Pubmed, incluindo artigos de 2005 a 2015,
assim como artigos de pesquisa cruzada com os artigos iniciais.
 Study conducted at the Departamento de Cirurgia, Faculdade de Medicina, Universidade do Porto, Porto, Portugal.
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E-mail: maricruznunes@live.com.pt (M.N. Magalhães).
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237-9363/© 2016 Sociedade Brasileira de Coloproctologia. Published by Elsevier Editora Ltda. This is an open access article under the CC
Y-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Resultados: Diversos estudos provam o papel do HPV como um fator de risco major no
desenvolvimento de carcinoma epidermóide do canal, assim como uma maior prevalência
desta neoplasia na populac¸ão HIV positiva e nos que praticam sexo anal recetivo. O trata-
mento continua a ser desde há duas décadas a quimioradioterapia, reservando a ressec¸ão
abdominoperineal para casos de falência do tratamento ou recorrência. A evidência avanc¸a
no  sentido de adequar o tratamento a cada doente, tendo em conta fatores prognósticos
individuais e as características biológicas do tumor.
Conclusões: O carcinoma epidermóide do canal anal é uma neoplasia associada ao HPV,
logo  deveria iniciar-se programas de rastreio e vacinar o sexo masculino como prevenc¸ão.
Muitos estudos são necessários para evoluir no tratamento, assim como na avaliac¸ão das
características biológicas do tumor.
©  2016 Sociedade Brasileira de Coloproctologia. Publicado por Elsevier Editora Ltda. Este
e´  um artigo Open Access sob uma licenc¸a CC BY-NC-ND (http://creativecommons.org/Introduction
Anatomy  and  histology  of  the  anal  canal
The anal canal measures approximately 4 cm in length, being
shorter in women. This channel is the lower portion of the
gastrointestinal tract.1 Its surgical margins are the anal verge
distally and the anorectal junction proximally.1,2
Histologically, in the anal canal, one can ﬁnd several types
of epithelia.1,2 Proximally, the channel is formed by colum-
nar epithelium similar to the intestinal epithelium, which, in
the anal canal, has folds in the mucous membrane forming
the anal columns. These columns are connected transversely
by folds called anal valves, which, together constitute the
pectineal line.1,2 The non-keratinized squamous epithelium
that is located distally to the pectineal line lacks hair folli-
cles and sebaceous and sweat glands, unlike the keratinized
epithelium which is continuous in the anal verge.1–4 in addi-
tion, between the pectineal line and the non-keratinized
squamous epithelium there is a transition zone in which the
epithelium may be of the columnar, cubic, transitional (as in
bladder), or squamous type. This transition zone is very spe-
ciﬁc to the anal area, and may also be called of cloacogenic
zone, for embryological reasons.1–4
Classiﬁcation  of  neoplasms  of  the  anal  canal
Classically, the generic term “anus” comprises the anal canal
and the anal verge.5 Thus, neoplasms of this zone are divided
between these two locations.5 The tumors of the anal verge,
known as perianal cancers, are identical to squamous or epi-
dermoid cutaneous tumors, and therefore do not enter into
the World Health Organization (WHO) classiﬁcation of diges-
tive tumors.5 In view of the lack of clarity between tumors of
the anal canal and anal verge, WHO  has proposed a pragmatic
deﬁnition, stating that “a tumor of the anal canal is a tumor
that cannot be seen entirely with the help of a subtle pull ofPlease cite this article in press as: Magalhães MN, Barbosa LE. 
http://dx.doi.org/10.1016/j.jcol.2016.08.003
the buttocks”.5 There are several types of tumors, depend-
ing on the type of epithelium involved, including squamous
or epidermoid tumor, which is the predominant histo-
logic type, while other rarer types include adenocarcinoma,licenses/by-nc-nd/4.0/).
neuroendocrine tumors, stromal tumors, lymphomas and sec-
ondary tumors.5
Given the similarities between the epidermoid carcinoma
of the anal canal and that of the uterine cervix, there is a cyto-
logical and histological classiﬁcation for anal lesions similar to
the classiﬁcation for the cervix.6 The modiﬁed Bethesda cyto-
logical classiﬁcation system divides squamous anal lesions
into high- and low-grade intraepithelial lesions, and these
lesions still have intermediate classiﬁcations, called “probable
low- and high-grade lesions”.6 There is also a classiﬁcation of
invasive squamous cell carcinoma.6
Despite the high malignant potential of the high-grade
intraepithelial lesions,7 less than 1% per year will progress to
cancer.3
Epidemiology  of  anal  canal  neoplasms
Malignant tumors of the anal canal represent 0.43% of all
malignancies and 2% of the digestive malignant tumors.5,8
Overall, the most prevalent cancer of the anal canal is squa-
mous cell carcinoma (85%), followed by adenocarcinoma
(10%). The other types are rare, representing less than 5% of
all diagnosed tumors of the anal canal.8
Anal cancer increased by 50% over the past 25 years, but
this is still a rare neoplasm.6 Its annual incidence has been of
1 in 100,000 people, and is higher in women. In the last two
decades, a signiﬁcant modiﬁcation in survival after 5 years was
not observed, ranging from 66% to 44% in Central and Eastern
Europe, respectively.9
Most existing epidemiological information refers to squa-
mous cell carcinoma. Thus, according to statistics, the
squamous cell type is more  prevalent in women, its risk
increases with age (the average age at diagnosis is 60 years)
and when it occurs in young, often these patients are
immunocompromised.5 However, the occurrence of diagnoses
in increasingly younger people has been found.6
MethodsAnal canal squamous carcinoma. J Coloproctol (Rio J). 2016.
The literature survey was conducted in Pubmed database.
The phrases “epidermoid carcinoma of the anal canal” and
“squamous cell carcinoma of the anal canal” were used. Only
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rticles published from 2005 to 2015 and performed in humans
ere considered. A language ﬁlter for search only in English,
ortuguese and Spanish was included. Opinion articles and
etters to the authors were excluded. After reading the title
nd abstract, and subject to an availability of the article, 36
rticles were obtained in Pubmed. Articles obtained by cross-
earching with the articles of the initial research and books
ith relevant information were also added.
esults
tiology  and  pathogenesis  of  squamous  cell  carcinoma
ome risk factors have been suggested for the development
f this neoplasm, particularly female gender, Human pap-
llomavirus (HPV) infection, history of sexually transmitted
isease, a number greater than 10 sexual partners, recep-
ive anal sex history, previous history of warts or genital
alignancy injuries, Human immunodeﬁciency virus (HIV)
nfection, immunosuppression, smoking, and prolonged use
f corticosteroids.3,4
Over the years, it has been found that HPV infection is an
mportant cause.10 Ouhoummane et al., in a study conducted
n Quebec, obtained results favoring this hypothesis.11 Ninety-
wo percent of cases of epidermoid carcinoma were colonized
ith HPV, and the most prevalent type was HPV 16.11
HPV infection is the most prevalent sexually transmitted
isease.12 This agent is a double-stranded DNA virus with
60 different types described and with speciﬁc tissue tropism.
hirty types exhibit tropism for anogenital epithelium, and
ypes 16 and 18 are those with greater malignant potential,
lthough they are also involved in benign lesions.12
The pathogenesis of the lesions caused by this agent in
he anal canal has been related to the pathogenesis in the
terine cervix.10 Similar to what happens in the cervix, the
arcinogenesis in the anal canal by HPV courses the following
ime sequence: Infection, persistence of infection, dysplasia
evelopment, and progression to an invasive cancer.10 These
teps can be reversed by the regression of the infection.10
Although the HPV life cycle in the epithelium of the cervix
nd in the anal canal is the same, the natural history of
he intraepithelial lesions is not identical, since the anatomy,
hysiology, and immune response are different in the cervix
nd in the anal canal.6
Initially, the method that the virus uses to colonize the
ost is to evade the innate immunity mechanisms, partic-
larly the physical barrier, antimicrobial peptides, Toll-like
eceptors, and various immune cells.6 Circumventing these
echanisms delays activation of adaptive immunity,6 which
acilitates virus entry into cells. By integrating into the host
enome, the virus will cause cellular changes that are pre-
ominantly the responsibility of two viral proteins, E6 and
7.13 One of the mechanisms used to modify the cell cycle
s the alteration of tumor suppressor genes.13 p16 (inhibitor
f kinase 4), a cell-cycle regulatory protein, interacts withPlease cite this article in press as: Magalhães MN, Barbosa LE. 
http://dx.doi.org/10.1016/j.jcol.2016.08.003
DK4 and CDK6 inhibiting the binding of these substances
o cyclin D and consequently reducing its kinase activity. This
nhibition prevents the phosphorylation of Rb protein, thus
nhibiting the transcriptional activation by the E2F complex,;x x x(x x):xxx–xxx 3
which, in turn, prevents the passage of G1 to the S phase of
the cell cycle.14 The E7 protein, by integrating into the genome,
changes the normal p16 protein functioning.6 On the other
hand, E6 is responsible for suppressing the normal functioning
of p53, another regulatory protein of the cell cycle and respon-
sible for activating the transcription of genes that encode
p16-like proteins.6 E6 protein also promotes the activation of
telomerase, perpetuating the transformation and immortal-
ization of the cell.6
The change of p16 and p53 expression has been linked
to HPV, to the point of differentiating HPV-positive and HPV-
negative cancer of the anal canal based on the deregulation of
the expression of these genes.13 The expression of p16 is the
most affected in cases of HPV infection, while p53 mutation
is associated with HPV-negative carcinoma.15 This distinction
between HPV-positive and HPV-negative carcinoma proves to
be important because there is a direct implication of the bio-
logical differences between the two types in the response to
treatment and in prognosis.13
As already mentioned in this paper, HIV infection is a risk
factor for squamous cell carcinoma.10 Even not being a pri-
mary  etiologic agent, HIV is a co-infection marker for other
sexually transmitted diseases, including HPV,10 and one may
observe a high prevalence of co-infection by HPV in HIV-
positive populations.16 However, not all patients infected with
HPV develop intraepithelial lesions resulting from infection.6
Over the years and especially in the era of antiretroviral ther-
apy, the carcinoma epidermoid of anal canal has become
the more  prevalent acquired immunodeﬁciency syndrome
(AIDS) non-deﬁning neoplasm in HIV-positive adult subjects,
being 30 times more  prevalent in this population than in the
general population.6 in addition to the higher incidence in
relation to the general population, patients with HIV also show
higher likelihood of progression to a high-grade, intraepithe-
lial lesion-invasive, anal carcinoma.17
Another already cited risk factor is the practice of receptive
anal intercourse.6 Some studies have compared the frequency
of high-grade intraepithelial anal lesions in HIV-positive and
HIV-negative men  who have anal sex with other men, and
the results revealed no signiﬁcant difference between these
groups.6 This ﬁnding may suggest that the immunological
deﬁcits in HIV infection may not play such a decisive role
as had been previously thought in the development of high-
grade lesions through high-risk HPV.6 Some studies conducted
speciﬁcally with HPV 16 found that in certain variants of the
virus there is a progression to carcinoma whether or not in
the presence of HIV infection and irrespective of CD4+ T-
lymphocyte count.6
Those studies which were conducted in order to evaluate
the impact of the immune system, particularly of regulatory
CD4+ T cells, in HPV infection, focused on intra-epithelial
lesions and on carcinomas of the uterine cervix.6 These stud-
ies showed that these cells play an important role in the
regression of infection, and consequently in the lesions caused
by HPV, especially HPV type 16.6 Therefore, given that the HIV
infection induces immunodeﬁciency in CD4+ lymphocytes,Anal canal squamous carcinoma. J Coloproctol (Rio J). 2016.
the HIV infection is considered as a risk factor for infection
by HPV, for intraepithelial lesions and for invasive anal car-
cinoma, taking into account the role of CD4+ T cells in the
control and progression of HPV infection.6 However, some
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authors stick to the hypothesis that there are other determi-
nants in the carcinogenesis process,6 taking into account that
the antiretroviral therapy did not reduce the incidence of anal
cancer in people with HIV.18
Prevention  and  screening
The identiﬁcation of a major etiological agent, such as HPV, has
allowed the development of a vaccine preventing infection by
certain strains, particularly the most common and pathologi-
cal, and concomitantly preventing squamous cell carcinoma.9
This vaccine has been developed in order to prevent carcinoma
of the cervix, however, it is anticipated it also prevents 80% of
anal carcinomata.9
Based on the results of cervical cytology in the prevention
of cervix carcinoma, screening programs with anal cytology
and high-resolution anoscopy have been proposed for risk
groups for anal cancer, including individuals practicing recep-
tive anal sex, HIV patients, and patients with a history of
anogenital malignancies caused by HPV.9 In conjunction with
the high-resolution anoscopy, one can add acetic acid, which
differentiates low-  and high-grade intraepithelial lesions, sta-
ining in white color those precursor lesions of high-grade
dysplasia.19
The screening can enable the identiﬁcation of malignan-
cies in their early stage and a timely treatment, as well as
the diagnosis of those precursor intraepithelial lesions, often
asymptomatic.20
Anal cytology has low sensitivity but great speciﬁcity.21
Inadequate specimen collection continues to be a major limi-
tation of this test, and this procedure should be improved for
making the anal cytology a recommended screening test for
all patients at risk of anal carcinoma.21
Diagnosis
Clinical history is always critical, regardless of the area of
medicine, and anal cancer is no exception. One must deter-
mine all the symptoms and predisponent risk factors that
could suggest this diagnosis.9
Anal carcinoma is characterized by an indolent natu-
ral history,9 with a presentation of anal bleeding, the most
common symptom,3 often confused with a bleeding of hem-
orrhoidal origin, which delays diagnosis.9 The second most
common symptom is proctalgia,3 which may be accompa-
nied by a mass, an ulcer which does not heal, itching, mucus
emission, fecal incontinence, and ﬁstulae.9 However, 20% of
patients are asymptomatic at diagnosis.22
Currently, the recommended diagnostic tests are the digi-
tal rectal examination and proctoscopy, that should be carried
out by an expert doctor and, if necessary, under sedation to
allow for an adequate histological biopsy, a critical step to
diagnosis.9,23 Additionally, a diagnostic test for HIV and a CD4+
T-lymphocyte count should be carried out.23
The gynecological exam is an important procedure for
female patients, in order to evaluate vaginal involvement,Please cite this article in press as: Magalhães MN, Barbosa LE. 
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especially in lower and earlier tumors, as well as to rule out the
presence of ﬁstulae.9 The gynecologic evaluation is also impor-
tant because often synchronous and metachronous genital
neoplasms related to HPV develop in the context of an anal6;x x x(x x):xxx–xxx
squamous cell carcinoma in women.9 A cytology test for cervix
cancer screening should also be held.23
Staging
For the staging of neoplasia, the TNM system is used. This
system is based on tumor size (T), on regional nodular involve-
ment (N), and on the presence of metastasis (M).9 Nodular
involvement is assessed taking into account the distance to
the primary site and not the number of nodes involved.9
Imaging evaluation is essential to assess local involvement,
with the help of nuclear magnetic resonance (NMR) images or
of an endoanal pelvic echography, a procedure quite effective
to determine the transmural depth of the tumor, especially in
the case of small T1 lesions, where this procedure shows better
accuracy.9 With magnetic resonance, one can obtain informa-
tion on the size of the tumor, invasion of adjacent organs, and
nodular involvement.9
Obtaining a thoracic and abdominal computed tomography
(CT) is also desirable, in order to detect distant metastases,9,23
which are present at diagnosis in 5–8% of cases.9 On the
other hand, one can also consider a PET (positron emission
tomography) study, although this does not replace a CT scan.23
However, when this procedure is performed with ﬂuorodeoxy-
glucose, shows high sensitivity to detect nodular involvement,
such that several studies have demonstrated a shift in the
tumor stage in 20% of cases.9,22 When this occurs, the trend
is in favor of increasing the stage, which changes the treat-
ment plan and inﬂuencing particularly the radiotherapy in
approximately 3–5% of cases.9 This technique is of importance
because at diagnosis nodal involvement is found in 30–40% of
cases.9 Additionally, an assessment by palpation of the pres-
ence of inguinal adenopathy, particularly surface and medial
ones,9,23 is critical; if detected, these injuries should be biop-
sied by ﬁne-needle aspiration,23 as well as those increased
nodes with more  than 10 mm,  detected on imaging studies.9
Inguinal lymph involvement is an independent prognos-
tic factor in patients with anal carcinoma.24 Therefore, to
improve the diagnostic accuracy with respect to node involve-
ment and radiotherapy regime, John Spratt in 2000 proposed
a sentinel lymphatic node biopsy as a diagnostic test of gan-
glion micro-metastases.25 At the same time, Spratt suggested
that the prophylactic surgical dissection of the inguinal lymph
nodes is not required, but may be curative in many  cases with
nodular involvement or which present a positive sentinel node
biopsy.25 However, due to the high false-negative rate found in
some studies, this procedure is not yet part of the routine tests
advised.24 However, Mistrangelo et al., in 2013, in the study in
which a review of clinical trials that assess the precision of
this technique was performed, obtained a false negative rate
of 3.7%, which was considered acceptable. These authors con-
cluded that the procedure can be performed in patients with
anal carcinoma and that this is an easy and perfectly feasible
technique, with a high detection rate of 98.4% reported in the
literature.24Anal canal squamous carcinoma. J Coloproctol (Rio J). 2016.
Treatment  and  complications
The main goal of treatment is to obtain a cure with locore-
gional control, concomitant with the preservation of anal
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phincter function and maintaining the best possible quality
f life.9
Treatment of squamous cell carcinoma of the anal canal
equires a multidisciplinary approach, essentially when in the
resence of a state of immunosuppression.26 The involve-
ent of radiotherapists, oncologists, surgeons, radiologists
nd pathologists is mandatory.9
Initially, up to the 1980s surgery was the treatment for all
nal carcinomas, mainly with abdominoperineal resection.9,23
everal studies carried out in the 1970s26 prompted the pub-
ication by Nigro et al. in 1983 of a study which concluded
hat combination therapy with chemotherapy and radiation
herapy was effective enough to dismiss surgery if the injury
ould have completely regressed, and that this was proven
hrough appropriate diagnostic ancillary laboratory tests.27
his conservative therapeutic strategy allowed an excellent
ocal control, disease-free survival, and quality of life.27
The exclusive use of surgery has a high recurrence and a
urvival at 5 years of 30–70%.23 This strategy also presents the
isadvantages of a permanent colostomy and high rates of
enitourinary complications.23 Chemoradiotherapy has given
etter results versus surgery, with fewer complications and a
urvival at 5 years of 61–85%.18
Thus, the standard treatment for non-metastatic squa-
ous cell carcinoma of the anal canal has been a
ombination therapy, with chemotherapy using 5-ﬂuorouracil
5FU) 750 mg/m2/day by continuous infusion and mitomycin
 (MMC)  12 mg/m2 on day 1 of each cycle,23 and radiotherapy
ith a radiation typically between 50 and 54 Gy,26 providing a
omplete regression in 80–90% of patients.9 These recommen-
ations are based on six multicenter clinical trials evaluating
he results of the combined treatment.28
Abdominoperineal resection and permanent colostomy are
rocedures reserved for patients with residual or recurrent
isease after a complete treatment of chemoradiotherapy.29
urgery after recurrence allows a local control in 60% of cases
nd a survival at 5 years of 30–60%.9 The fact that we are in
ace of a radical surgical intervention, in an irradiated site,
ncreases the risk of complications of the surgical wound.26
n order to minimize these complications, a myocutaneous
econstruction using the rectus abdominis muscle can be held,
nd that was shown to be an effective technique.26
The risk of needing a permanent colostomy has been eval-
ated in several studies, with the conclusion that there are
retreatment independent risk factors, particularly male gen-
er, tumor size, and hemoglobin levels, that may prove useful
or prediction of combination therapy failure, with the possi-
ility of offering to these patients the surgical treatment as an
nitial therapy.30
One consideration that must be borne in mind during
reatment is HIV infection.26 Other than immunosuppres-
ion, these patients show little tolerance to the treatment
nd a poorer toxicity proﬁle.26 Some studies have found that
IV-positive patients have a worse prognosis with chemora-
iotherapy than HIV-negative patients.31 One of the problems
ith the treatment are the high doses of radiation, poorly tol-Please cite this article in press as: Magalhães MN, Barbosa LE. 
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rated by patients with HIV. Some studies have proposed to
educe the dose commonly used in favor of less toxic lev-
ls that could simultaneously achieve the regression of the
eoplasm.26 Most of these patients who showed a proﬁle of;x x x(x x):xxx–xxx 5
little tolerance with routine radiation levels had a low
CD4+ cell count.26 Thus, some studies suggest initiating an
antiretroviral therapy in order to increase the patient’s CD4+
cell count to more  than 200 cells/L, before starting the treat-
ment for anal carcinoma.23,28 This strategy is supported by
Wexler et al., that, in their study, obtained therapeutic out-
comes similar both in HIV-negative and HIV-positive patients
treated with antiretroviral therapy.32 However, these authors
found signiﬁcant toxicity in HIV-positive patients with the
standardized treatment for anal carcinoma, despite the con-
trolled viral load levels and CD4+ cell counts.32 On the other
hand, evidence suggests that after the implementation of the
appropriate treatment of the HIV infection, the treatment for
anal carcinoma is standardized, that is, a combination ther-
apy using 5-FU and, and radiotherapy with normal radiation
doses.28,33
Although we refer to the usual doses of radiation, the
truth is that the optimal dose of radiation has not yet been
established, nor the ideal scheme.28,34 There are different
approaches to radiation therapy, but in general conventional
radiotherapy encompasses primary tumor and affected local
lymph nodes.9 A number of studies suggest that the opti-
mal  dose of radiation varies with the tumor; there are tumors
that need a higher dose, as well as others that may regress
at a lower dose.35 Thus, a biomarker would be useful for the
prediction of tumor response. Accordingly, multi-parameter
magnetic resonance is used as such in other squamous car-
cinomas during chemoradiotherapy, and there is evidence
which suggests its effectiveness in the anal squamous car-
cinoma as a predictor of the individual patient response,
allowing an adjustment of the dose and of the radiation ther-
apy regimen.35
Another group that should be taken into account when
using radiotherapy are the elderly, as this age group may not
tolerate the full dose of radiation commonly used.3 This puts
them at risk of being undertreated; thus, the current recom-
mendations are that one do not evaluate the suitability of
radiotherapy only taking into account the patient’s age, but
also assessing his/her physiological status, which has been
increasingly better with the increase in mean life expectancy.9
The high toxicity of radiation therapy has stimulated
the use of more  conformational techniques, with a three-
dimensional planning that allows a more  directed approach,
such as modulated-intensity radiotherapy,26 which has
proven to reduce morbidity in some studies, particularly in
the Radiation Therapy Oncology Group (RTOG) 0529 study.36
This technique achieves in a lesser degree the adjacent organs
free of neoplasia, as the bladder, rectum, small intestine, gen-
itals, femoral head, and perianal skin.9,26 With the use of this
technique, one can achieve a full dose in a shorter period of
time.9
Brachytherapy is a variant of conventional radiotherapy
but at an interstitial level, in which a high dose of radia-
tion, directly in contact with the primary tumor, is emitted,
not reaching the normal surrounding tissue, the contralateral
mucosa, and the sphincter.9 In isolation, brachytherapy is notAnal canal squamous carcinoma. J Coloproctol (Rio J). 2016.
recommended, but the technique can be used after a response
to standard chemoradiotherapy.9 However, Falk et al. in 2014
published the results of a clinical trial, in which these authors
concluded that high-dose brachytherapy is an excellent
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Studies related to serum antigen from squamous carci-
noma established a correlation between pretreatment serum6  j coloproctol (rio j).
technique for speciﬁcally targeting tumors and reducing the
total time total of treatment.37
The acute toxicity of radiation therapy involves primarily
the skin, yielding a radiation dermatitis, hematologic com-
plications, including myelosuppression; on the other hand,
the patient may also present with fatigue and gastrointestinal
complications.9,26 The long-term complications can be ﬁbrosis
of the rectum and anal canal, anal sphincter dysfunction, skin
irritation, vaginal atrophy, and erectile dysfunction3,35; radia-
tion enterocolitis can also occur and is a severe, however rare,
adverse side effect.38
Side effects and long-term complications of radiotherapy
and chemotherapy have raised the hypothesis of using alter-
native treatments, such as submucosal endoscopic dissection,
restricted to carcinomas in situ, and that has proved success-
ful in similar squamous carcinomas in the esophagus and
pharynx.38
Metastatic disease occurs in 10–20% of patients, and the
most affected sites are distant lymph nodes, liver, and lung.29
The less affected sites are the peritoneum, bones, brain
and skin.29 The 5-year survival for these patients, reported
in the literature, is 18–21%.29 The mean time to onset of
metastatic disease was 2 years after treatment for in situ anal
carcinoma.18
Due to the low prevalence of metastasized anal carcinoma,
no clinical phase III clinical study was completed on the
treatment of squamous cell carcinoma of the metastasized
anal canal.26 Currently, the only recommended treatment for
patients with distant metastases or with local recurrence unﬁt
for surgery is chemotherapy with cisplatin and 5-FU, due to the
hematological toxicity associated with the prolonged use of 5-
FU and MMC,9 with a one-year survival rate of 62.2% and with
a 5-year survival of 32.2%, and mean survival of 34.5 months.39
Cisplatin was also studied in patients with in situ anal carci-
noma in place of MMC,  and showed similar results, and that
drug can be considered for combination therapy with 5-FU, not
only in cases of metastatic carcinoma as in carcinoma locally
advanced.40
The treatment regimen consists of a continuous infu-
sion of 5-FU 750 mg/m2/day for 5 days, and an intravenous
dose 75 mg/m2 of cisplatin on day one every 28 days.18,39
Phase II studies comparing 5-FU and cisplatin with carboplatin
and paclitaxel for the treatment of metastatic squamous cell
carcinoma of the anal canal are underway, but with limita-
tions, since 5-FU/cisplatin combination is most widely used,
which makes difﬁcult a direct comparison between the two
combinations.18,26 Trials with other chemotherapeutics that
have proven effective in other squamous carcinomas are
also under way.39 The results reported by Kim et al. sug-
gest that the combination of docetaxel, cisplatin, and 5-FU
can be beneﬁcial for the remission of long-term metastatic
anal carcinoma, however the number of patients is again a
restriction.41
Palliative surgery and radiation should be considered in
the treatment of such patients.26 Eng et al. showed that
patients undergoing resection of metastases, notably liver,Please cite this article in press as: Magalhães MN, Barbosa LE. 
http://dx.doi.org/10.1016/j.jcol.2016.08.003
obtain better results in disease-free time and mean survival,
when compared with patients not undergoing resection of
metastases.23 However, this procedure is not recommended,
and more  studies are needed to explore surgical criteria.236;x x x(x x):xxx–xxx
Squamous cell carcinoma of the anal canal, as well
as other squamous carcinomas in other sites, exhibits an
increased expression of epidermal growth factor receptors
(EGFR), also known as HER-1 and c-erB-1.26 Biological ther-
apy targeting these receptors have been widely developed in
the treatment of other squamous carcinomas, and recently
clinical trials have been conducted in order to evaluate
their effectiveness in locally advanced and metastatic anal
carcinomata.23
Follow-up
There is controversy regarding the period of time that
must elapse to consider that chemoradiotherapy had failed;
typically, 6 months should elapse for the occurrence of
tumor regression, but in some patients, the period may be
longer.23
Patients in complete remission are referred for magnetic
resonance imaging every 6 months for 3 years, as evidence
suggests that only <1% of tumors will recur after 3 years.9
Anoscopy is highly painful in these patients undergoing radi-
ation therapy, so this procedure is not recommended.9 Any
suspicious lesion should be biopsied.9
Patients undergoing abdominoperineal resection for lack of
therapeutic response or recurrence should be reassessed every
3–6 months for 5 years, with a clinical evaluation. Additionally,
these patients should perform a chest and abdominal CT and
a pelvic NMR annually for 3 years.23
Immunodepressed patients should be evaluated every 4
weeks from the onset of treatment, in order to monitor
regressions.23
Prognosis
Poor prognostic factors for anal cancer include male gender,
positive lymph nodes (especially inguinal nodes), and primary
tumor >5 cm.9 Skin ulceration was also identiﬁed in clinical
trials as a poor prognostic factor for local control and mean
survival.9 Baseline hemoglobin levels were also pointed out as
a prognostic factor for poor local-regional control, death, and
low mean survival.9 Smokers with anal carcinoma appear to
have a worse mean survival, when compared to nonsmoker
patients.9
In squamous carcinomas of the pharynx and larynx, a bet-
ter prognosis was seen, when HPV infection and mutation of
p16 were detected, with consequent abnormal expression.42
Meulendjiks et al. proved in their study that the presence
of HPV infection and of an alteration of p16 expression in
patients with squamous cell carcinoma of the anal canal
also provide a better prognosis, taking into account that
these patients showed better local-regional control and mean
survival.15Anal canal squamous carcinoma. J Coloproctol (Rio J). 2016.
levels and clinical classiﬁcation of the tumor, nodular involve-
ment, response to therapy, risk of recurrence, and death. Their
authors concluded that elevated serum levels of antigen were
related with a worse prognosis.43
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iscussion
fter this systematic review, it appears that there is still much
o be clariﬁed, especially in the treatment area. Despite a ris-
ng incidence of anal carcinoma, the low number of patients
nd the exclusion of HIV-positive patients in clinical trials,
n whom the prevalence of this disease is higher, have not
llowed the completion of studies evaluating new therapies.
Recently, some studies have included patients with HIV in
linical trials,23 which is crucial since there is much contro-
ersy on the possible increased toxicity with the use of the
tandard treatment in these patients, in addition to allowing,
s already mentioned, a larger sample with more  signiﬁcant
nd generalizable results, since one of the limitations of those
tudies excluding patients with HIV is that they do not allow
 generalization of their results to this population. Similarly,
omen should be included in studies that test receptive anal
ntercourse as a risk factor, since most studies have only
eported this inﬂuence in men, excluding women with the
ame sexual behavior.
As stated above, a reduction of 80% of anal cancers with
he administration of the HPV vaccine occurs; it appears,
herefore, that the national vaccination plan should also be
xtended to men.
The treatment of both local and metastatic carcinoma has
hown little progress in the last two decades, again thanks
o the shortage of the number of patients; however, positive
esults begin to emerge in studies testing therapies that have
roved effective in other squamous carcinomas from other
ites, notably biological therapy.
The suitability of the individual use of radiotherapy, tak-
ng into account the individual prognostic factors (already
entioned) and the biological characteristics of the tumor, is
 promising strategy. In line with this, more  directed radia-
ion techniques have evolved and are of extreme importance
n order to reduce the toxicity, morbidity, and the impact on
uality of life.
onclusion
quamous cell carcinoma of the anal canal is one of the most
revalent malignancies in patients with HIV, which is a risk
actor for HPV infection, which in turn is a major cause of anal
arcinoma. Receptive anal sex is also an important risk factor.
Some studies have been published and continue to emerge
n an attempt to ﬁnd more  effective and alternative cytostatic
gents; however, we  do not count on a sufﬁcient body of evi-
ence in order to replace the recommended combination of
-FU and MMC  in localized carcinomata, and of 5-FU and cis-
latin in metastatic tumors.23
Many  studies are needed to promote progress in the treat-
ent of squamous cell carcinoma of the anal canal, as well as
n the evaluation of the biological characteristics of the tumorPlease cite this article in press as: Magalhães MN, Barbosa LE. 
http://dx.doi.org/10.1016/j.jcol.2016.08.003
hat enable a prognosis of the answer to treatment, besides an
ndividual and more  effective therapeutic suitability. On the
ther hand, considering that this neoplasia is a preventable
isease in most cases, in the future, one can count on advances
1;x x x(x x):xxx–xxx 7
in primary and secondary prevention through vaccination and
screening, respectively.
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